Veracyte CEO exercises options, sells 138K shares

Veracyte, Inc. chief executive Marc Stapley reported an exercise-and-sale transaction in company stock.

Rhea-AI Filing Summary

Veracyte, Inc. chief executive Marc Stapley reported an exercise-and-sale transaction in company stock. On June 4, 2026 he exercised stock options covering 138,051 shares of common stock at $36.60 per share and sold the same 138,051 shares in open-market trades at a weighted average price of $50.1234 per share pursuant to a Rule 10b5-1 plan.

The filing shows 9,012 shares of common stock were withheld on June 2, 2026 to cover tax obligations tied to vesting restricted stock units, which the company notes does not represent a sale. Following these transactions, Stapley directly owns 440,494 shares of Veracyte common stock.

Insider Trade Summary 10b5-1

Exercise and Sale: 138,051 shares ($1.87M approx. pre-tax spread)

Exercise and Sale 4 txns

Insider Stapley Marc

Role Chief Executive Officer

Sold 138,051 shs ($6.92M)

Approx. gross sale proceeds $6.92M

Approx. exercise cost $5.05M

Approx. pre-tax spread $1.87M

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	138,051	$0.00	$0.00
Exercise	Common Stock	138,051	$36.60	$5.05M
Sale	Common Stock	138,051	$50.1234	$6.92M
Exercise Price or Tax Liability	Common Stock	9,012	$47.80	$431K

Holdings After Transaction: Stock Option (right to buy) — 0 contracts (Direct); Common Stock — 440,494 shares (Direct)

Footnotes (5)

1. F1. Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of certain restricted stock units on June 2, 2026 and does not represent a sale.
2. F2. Due to an administrative error, shares of common stock acquired by the Reporting Person under the Veracyte, Inc. Employee Stock Purchase Plan on July 31, 2025 were incorrectly reported as 529 shares of common stock instead of 382 shares of common stock in a Form 4 filed on September 4, 2025, and these shares were overreported in subsequent Forms 4 filed by the Reporting Person. This column reflects the corrected balance.
3. F3. The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 24, 2025.
4. F4. Represents weighted average sales price. Sale prices for the transactions range from $50.00 to $50.52. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
5. F5. The option is fully vested.

Key Figures

Shares sold: 138,051 shares Weighted average sale price: $50.1234 per share Option exercise price: $36.60 per share +3 more

6 metrics

Shares sold 138,051 shares Open-market sale of common stock on June 4, 2026

Weighted average sale price $50.1234 per share Common stock sold on June 4, 2026

Option exercise price $36.60 per share Stock options exercised for 138,051 shares

Shares withheld for taxes 9,012 shares Tax withholding on RSU vesting June 2, 2026

Shares owned after transactions 440,494 shares Direct Veracyte common stock holdings post-transaction

Option expiration date June 1, 2031 Original expiration for exercised stock option grant

Key Terms

Rule 10b5-1 plan, restricted stock units, weighted average sales price, Employee Stock Purchase Plan, +1 more

5 terms

Rule 10b5-1 plan regulatory

"The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

restricted stock units financial

"withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of certain restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average sales price financial

"Represents weighted average sales price. Sale prices for the transactions range from $50.00 to $50.52."

Employee Stock Purchase Plan financial

"shares of common stock acquired by the Reporting Person under the Veracyte, Inc. Employee Stock Purchase Plan"

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

tax withholding obligations financial

"withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Veracyte (VCYT) CEO Marc Stapley report?

Marc Stapley reported exercising options for 138,051 Veracyte shares at $36.60 and selling the same 138,051 shares in open-market trades at a weighted average price of $50.1234 per share, all under a pre-arranged Rule 10b5-1 trading plan.

How many Veracyte (VCYT) shares does CEO Marc Stapley own after this Form 4?

After the reported transactions, Marc Stapley directly owns 440,494 shares of Veracyte common stock. This figure reflects the option exercise, subsequent sale of 138,051 shares, and tax-related share withholding disclosed for June 2026 in the Form 4 filing.

Was Marc Stapley’s Veracyte (VCYT) stock sale pre-planned under Rule 10b5-1?

Yes. The Form 4 states the transactions were made under a Rule 10b5-1 plan adopted by Marc Stapley on November 24, 2025. Such plans pre-schedule trades, indicating the sale timing was arranged in advance rather than decided opportunistically.

What price range did Veracyte (VCYT) CEO Marc Stapley receive for the sold shares?

The Form 4 reports a weighted average sales price of $50.1234 per share for the 138,051 shares sold. A footnote explains the individual sale prices ranged from $50.00 to $50.52 per share, with detailed breakdowns available upon request to stakeholders.

Did the Form 4 report any Veracyte (VCYT) shares sold to cover taxes?

No shares were sold for taxes; instead, 9,012 shares were withheld to satisfy Marc Stapley’s tax obligations related to restricted stock unit vesting. The filing specifies this withholding on June 2, 2026 does not represent a sale transaction in the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/04/2026 - 09:38 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stapley Marc

(Last) (First) (Middle)

6000 SHORELINE COURT

SUITE 300

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
VERACYTE, INC. [ VCYT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/02/2026		F(1)		9,012	D	$47.8	440,494(2)	D
Common Stock	06/04/2026		M(3)		138,051	A	$36.6	578,545	D
Common Stock	06/04/2026		S(3)		138,051	D	$50.1234(4)	440,494	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$36.6	06/04/2026		M(3)			138,051	(5)	06/01/2031	Common Stock	138,051	$0	0	D

Explanation of Responses:

1. Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of certain restricted stock units on June 2, 2026 and does not represent a sale.

2. Due to an administrative error, shares of common stock acquired by the Reporting Person under the Veracyte, Inc. Employee Stock Purchase Plan on July 31, 2025 were incorrectly reported as 529 shares of common stock instead of 382 shares of common stock in a Form 4 filed on September 4, 2025, and these shares were overreported in subsequent Forms 4 filed by the Reporting Person. This column reflects the corrected balance.

3. The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 24, 2025.

4. Represents weighted average sales price. Sale prices for the transactions range from $50.00 to $50.52. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

5. The option is fully vested.

Remarks:

	/s/ Jonathan Wygant, as attorney-in-fact	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)